loader image

Our Science

Deriving drugs from bacterial metabolites found in man means no genotoxicity, faster clinical development and safer treatments.

Our pipeline includes treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/Recurrence in Leukemias, and other diseases.

Safer, Faster to Market and Lower R&D Cost

Our microbiome-derived drugs are derived from natural substances, and enable a new platform for developing treatments which have the potential to treat over 85 chronic inflammatory diseases currently afflicting patients; providing safer treatments than current therapies.